Biocompatibility Testing

Biocompatibility Testing designates systematic evaluation of the potential for medical devices, container closure systems, drug delivery components, and biomaterials to cause adverse biological responses through direct or indirect patient contact, following ISO 10993 standards addressing cytotoxicity, sensitisation, irritation, systemic toxicity, genotoxicity, and implantation effects.

The pharmaceutical industry conducts biocompatibility testing for combination products, drug delivery devices, packaging materials, and single-use manufacturing components that contact drug products. Container closure systems including vials, stoppers, and prefilled syringes require extractables and leachables evaluation followed by toxicological risk assessment. Infusion devices and implantable drug delivery systems require comprehensive biocompatibility programmes addressing all relevant endpoints. Single-use bioprocessing equipment requires demonstrating acceptable biological safety when extractables contact drug substance or product. Regulatory submissions include biocompatibility risk assessments justifying material selections. As novel drug delivery systems and combination products proliferate, biocompatibility evaluation continues ensuring patient safety.